FULL LENGTH ARTICLE

Ubiquitin ligase DTX3 empowers mutant p53 to promote ovarian cancer development

Shanshan Wang a,b,1, Qian Hao a,b,1, Jiajia Li b,c,1, Yajie Chen b,d, Hua Lu e, Xiaohua Wu b,c,* , Xiang Zhou a,b,f,g,**

a Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, PR China
b Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China
c Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, PR China
d Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, PR China
e Department of Biochemistry & Molecular Biology and Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA 70112, USA
f Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, PR China
g Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, PR China

Received 5 August 2020; received in revised form 1 November 2020; accepted 13 November 2020
Available online 21 November 2020

KEYWORDS
DTX3;
E3 ubiquitin ligase;
Invasion;
Mutant p53;
Ovarian cancer;
Proliferation

Abstract The deltex family protein DTX3 is believed to possess E3 ubiquitin ligase activity, as it contains a classic RING finger domain. However, its biological role and the underlying mechanism in cancer remain largely elusive. Here, we identified DTX3 as a novel mutant p53-interacting protein in ovarian carcinoma. Mechanistically, DTX3 mediated mutant p53 ubiquitination and stabilization by perturbing the MDM2-mutant p53 interaction, consequently leading to activation of diverse mutant p53 target genes. Importantly, a positive correlation between the expression of DTX3 and mutant p53 target genes was further validated in ovarian carcinomas. Ectopic DTX3 promoted, while depletion of DTX3 suppressed, ovarian cancer cell proliferation and invasion. Remarkably, the pro-tumorigenic effect of DTX3 is dependent on mutant p53, because ablation of mutant p53 significantly impaired DTX3-induced gene expression and ovarian cancer cell growth and propagation. Furthermore, DTX3 elevated the

* Corresponding author. Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, PR China.
** Corresponding author. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
E-mail addresses: wu.xh@fudan.edu.cn (X. Wu), xiangzhou@fudan.edu.cn (X. Zhou).
Peer review under responsibility of Chongqing Medical University.
1 Equal contribution.

https://doi.org/10.1016/j.gendis.2020.11.007
2352-3042/© 2020, Chongqing Medical University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Epithelial ovarian cancer (EOC) is one of the leading causes of cancer-related death in women worldwide. The frontline treatment includes primary debulking surgery followed by chemotherapy, whereas most patients die from the relapsed disease that eventually progresses to a more aggressive stage. Although our understanding of the etiology and pathology of EOC has been advanced, the overall survival of the disease has not been significantly improved for decades. Thus, systematic dissection of the mechanisms behind ovarian carcinogenesis, progression, and refractoriness remains an active area of investigation.

Mutation of the tumor suppressor gene TP53 is both an early event and an important characteristic of high-grade serous ovarian carcinoma (HGSOc) that is the most common and aggressive histotype of EOC. The TP53-encoded protein p53 is regarded as the “guardian of the genome” to prevent cells from malignant transformation by transcriptionally modulating the expression of a cluster of genes, such as CDKN1A, BTG2, and GADD45A, involved in cell cycle arrest and DNA repair. Moreover, p53 also eliminates cancer cells by driving irreversible cellular outcomes, including cell senescence, apoptosis, and ferroptosis. Mutation of TP53, which is associated with cancer initiation and development, not only abrogates or counteracts the tumor suppressive activity of wild-type p53 (wtP53), but also endows mutant p53 (mtp53) with oncogenic function, namely “gain-of-function” (GOF), resulting in enhanced cancer cell survival, proliferation, and metastasis. Various working models have been proposed accounting for mtp53’s GOF. As a vast majority of missense mutations occur in the DNA-binding domain (DBD), mtp53 proteins are usually deprived of the ability to associate with the canonical p53-responsive DNA elements. Nevertheless, mtp53 can indirectly bind to different DNA elements and regulate gene transcription via interaction with other transcription factors. For instance, CDK4/Cyclin D mediates phosphorylation of mtp53-R249S, a liver cancer-derived hotspot p53 mutant, which translocates to the nucleus and promotes rRNA transcription by interacting with c-MYC. In the rare case, mtp53-R273P was found to associate with the specifically structured DNA, such as matrix attachment regions (MARs), to induce gene transcription. In addition, some p53 mutants, such as R248W and R273H, were shown to execute GOF by binding to proteins unrelated to transcription and modulating their functions. In ovarian cancer, mtp53 was considered a driver for cancer onset and progression, as well as a biomarker for targeted therapy. Recently, we also revealed that mtp53-S241F and R273H endorse ovarian cancer development by transcriptionally activating a myriad of genes associated with cell survival, proliferation, metastasis, and metabolism. Because of the complex interplays between mtp53 and its partnerships, additional efforts are needed to delineate the mtp53 network in ovarian cancer, which would provide useful information for future development of therapeutic approaches.

In our attempt to explore mtp53-interacting proteins in primary ovarian cancer tissues as previously described, the deltex E3 ubiquitin ligase 3 (DTX3), also known as RNF154, was revealed as an additional mtp53-binding partner that is further detailed below. Deltex (dx) was initially identified as a positive regulator of Notch function in Drosophila. Mammalian homologues of Delte, including DTX1 to 4 and a distantly related protein DTX3L, compose the DTX protein family that shares a highly conserved C-terminal region harboring a classic RING finger domain. DTX1, DTX2, and DTX4 were shown to interact with the intracellular ankyrin repeats of NOTCH via the N-terminal basic domains, leading to deregulation of the Notch signaling in embryogenesis, lymphocyte development, and several types of cancer. Nevertheless, the understudied member DTX3 was believed unable to bind to NOTCH, owing to lack of the N-terminal module critical for the interaction between DTX proteins and NOTCH receptors. An integrated genomic screening showed that DTX3 is amplified in the luminal-subtype of breast cancer, which is associated with highly proliferative luminal tumors and poor prognosis. However, the biological function and molecular basis of DTX3 during cancer development remain largely elusive.

In this study, we identified DTX3 as a mtp53-interacting protein through a co-immunoprecipitation (IP) assay coupled with mass spectrometry (MS) analysis as described. This interaction was further validated in cancer cells. DTX3 mediated mtp53 poly-ubiquitination and protein stability, leading to induction of diverse mtp53 target genes that are required for cancer cell proliferation and metastasis. Consistently, we showed that ectopic expression of DTX3 prompts, whereas ablation of DTX3 inhibits, ovarian cancer cell growth and invasion in a mtp53-dependent fashion. Finally, DTX3 endorsed ovarian tumor growth in vivo and was associated with unfavorable prognosis of ovarian cancer. Hence, this study unveils DTX3 as an oncoprotein that can promote mtp53 activity in ovarian cancer.
Materials and methods

Cell culture and transient transfection

Human cancer cell lines ES-2, OVCA420, SKOV3, HCT116\(^{53}\) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 0.1 mg/ml streptomycin. All cells were maintained at 37 °C in a 5% CO\(_2\) humidified atmosphere. Cells were seeded on plates at appropriate density 12–24 h before transfection, and then transfected with plasmids or siRNAs using Hieff Trans™ liposomal transfection reagent following the manufacturer’s protocol (Yeasen, Shanghai, China). Cells were harvested or collected at 36–48 h post-transfection for future experiments. Proteasome inhibitor MG132 (Sigma—Aldrich St. Louis, MO, USA) treatment was conducted 4–6 h before cell harvest.

Plasmids and antibodies

The Flag-tagged DTX3-expressing plasmid was purchased from Vigene Biosciences, Inc. (Shandong, China). The Myc-tagged DTX3 plasmid was generated by inserting the full-length cDNA amplified by PCR into the pcDNA3.1/Myc-His vector, using the following primers, 5′-GGAATT-CATGCTGGTCTGCTCTGACC-3′ and 5′-CGGGATCCGTCCTGTCC-3′. The plasmids encoding non-tagged mtp53 (R175H, S241F, R248W, and R273H), His-Ub and HA-GATACCCTTCGC-3′. The plasmids encoding non-tagged e-cadherin (Catalogue No. 1:1166551, Arigo), and the light chain-specific secondary mouse anti- CXCL1, ABCB1, CDC25C, MCM6, KIF20A, CDK1, DEPDC1, MAP2K3, MYC, MMP13, MMP3, NCAPH, FACTIN, CENPA, 5′-GAGATGAGACTGGATACCCATG-3′; MAD1L1, 5′-GCACTGGAGATCGAGTACCCATG-3′; GAPDH, 5′-GGAGGGAACTGAGACTGGATAGAG-3′; β-actin (Catalogue No. 60008-1-Ig, Proteintech), anti-DX1 (Catalogue No. 1:5695351, Arigo) and mouse (Catalogue No. ARG65350, Arigo), and the light chain-specific secondary mouse antibody (Catalogue No. 115-035-174, Jackson) were commercially purchased.

Reverse transcription and quantitative RT-PCR analysis

Total RNAs were isolated using the RNAsio Plus reagent (Takara, Japan) following the manufacturer’s protocol. 0.5–1 μg total RNAs were used as templates for reverse transcription using the PrimeScript™ RT reagent Kit with gDNA Eraser (Takara, Japan). Quantitative RT-PCR (RT-qPCR) was conducted using TB Green™ Premix according to the manufacturer’s protocol (Takara, Japan). The primers for DTX3, CXCL1, ABCB1, CDC25C, MCM6, KIF20A, CDK1, DEPDC1, MAD1L1, and GAPDH cDNA detection were as follows: DTX3, 5′-GGAATT-CATGCTGGTCTGCTCTGACC-3′ and 5′-CGGGATCCGTCCTGTCC-3′; CXCL1, 5′-GCACTGGAGATCGAGTACCCATG-3′; ABCB1, 5′-GAGATGAGACTGGATACCCATG-3′; CDC25C, 5′-GCACTGGAGATCGAGTACCCATG-3′; MCM6, 5′-GAGATGAGACTGGATACCCATG-3′; KIF20A, 5′-GCACTGGAGATCGAGTACCCATG-3′; CDK1, 5′-GCACTGGAGATCGAGTACCCATG-3′; GAPDH, 5′-GGAGGGAACTGAGACTGGATAGAG-3′; β-actin (Catalogue No. 60008-1-Ig, Proteintech), anti-DX1 (Catalogue No. 1:5695351, Arigo) and mouse (Catalogue No. ARG65350, Arigo), and the light chain-specific secondary mouse antibody (Catalogue No. 115-035-174, Jackson) were commercially purchased.

Immunoblotting

Cells were harvested and lysed in lysis buffer consisting of 50 mM Tris/HCl (pH7.5), 0.5% Nonidet P-40 (NP-40), 1 mM EDTA, 150 mM NaCl, 1 mM dithiothreitol (DTT), 0.2 mM phenylmethylsulfonyl fluoride (PMSF), and the protease inhibitor cocktail (Yeasen), and then incubated on ice for 45–60 min. Equal amounts of clear cell lysates (20–80 μg) were used for immunoblotting (IB) analysis as described previously.\(^{34}\)

Immunoprecipitation

Immunoprecipitation (IP) was conducted using α-Flag or α-DO-1 antibodies as indicated in the figure legends. Briefly, ~5000–1000 μg of proteins were incubated with the indicated antibody at 4 °C for 4 h or overnight. Protein A/G beads (Santa Cruz Biotechnology) were then added to the mixture that was further incubated at 4 °C for additional 1–2 h. Beads were washed at least three times with lysis buffer. Bound proteins and 10% inputs were analyzed by IB with antibodies as indicated in the figure legends.

In vivo ubiquitination assay

HCT116\(^{53}\) were transfected with combinations of plasmids encoding mtp53-R273H, His-Ub or Flag-DTX3 as indicated in the figure legends. MG132 was added to...
cultures 4–6 h before harvest. At 48 h after transfection, cells were harvested and split into two aliquots, one for IB and the other for the ubiquitination assay. Briefly, cell pellets were lysed in buffer I (8 M urea, 0.1 M Na2HPO4/NaH2PO4 (pH 8.0), 10 mM Tris–HCl (pH 8.0), 10 mM β-mercaptoethanol, 5 mM imidazole) and incubated with Ni-NTA beads (Takara, Japan) that capture His-tagged proteins/complex at room temperature for 4–6 h. Beads were washed twice with buffer I, and twice with buffer II (8 M urea, 0.1 M Na2HPO4/NaH2PO4 (pH 6.3), 10 mM Tris–HCl (pH 6.3), 10 mM β-mercaptoethanol). The captured proteins were eluted and analyzed by IB with the indicated antibodies.

RNA interference

The siRNA against DTX3 were synthesized and purified by GenePharma (Shanghai, China). The siRNA sequences used were as follows: siDTX3-1, 5'-GGAGACGCACATCCACCAACAA-3', si-DTX3-2, 5'-GGCGGGAGCTGTCTCTAAGG-3', and sip 53, 5'-GUAACUCUGGGACCGG-3'. The siRNAs of 50–100 nM were transfected into cells using Hieff Trans™ liposomal transfection reagent following the manufacturer’s protocol (Yeasten). Cells were harvested 48–72 h after transfection for IB or RT-qPCR.

Generation of stable cell lines

The lentivirus-based pLenti-EF1a-EGFP-Puro-CMV plasmids encoding DTX3 and mtp53-R273H were purchased from Vigene Biosciences (Shandong, China) and OBio Technology (Shanghai, China), respectively. The recombinant viruses were packaged as described35 and infected cells with appropriate amounts for overnight. The stable cells were selected with 1 µg/ml puromycin.

Cell viability assay

To assess the long-term cell survival, the Cell Counting Kit-8 (CCK-8) (Dojindo, Japan) was used according to the manufacturer’s instructions. Cell suspensions were seeded at 3000 cells per well in 96-well culture plates at 12 h post-transfection. CCK-8 at a final concentration of 10% was added to the cultures for 2–4 h, and the absorbance of the samples was measured at 450 nm using a Microplate Reader every 24 h.

Transwell invasion assay

The invasion assay was performed using Transwell chamber inserts in a 24-well plate as described.23 Briefly, 5 × 10^4 cells suspended in 100 µL of serum-free medium were added to the upper chamber. The lower chambers were filled with the normal culture medium. The cells were cultured for 24–36 h at 37 °C. Afterward, the cells on the upper surface were scraped and washed away, and the cells on the lower surface were fixed with methanol and stained with 0.1% crystal violet. The number of invaded cells was counted in at least five randomly selected fields under an optical microscope by image J software.

Flow cytometry analysis

The PE Annexin V Apoptosis Detection Kit I (BD Biosciences, San Diego, CA, USA) was used for apoptosis analysis according to the manufacturer’s instruction. Briefly, cells were washed twice with cold PBS, resuspended in binding buffer, and stained with PE Annexin V and 7-AAD for 15 min at RT. The cells were then analyzed by a FC500 MPL flow cytometer (Beckham coulter, Indianapolis, IN, USA).

Mouse xenograft experiment

Female BALB/c nude mice of five weeks were purchased from the Department of Laboratory Animal Science in Shanghai Medical College of Fudan University. To evaluate the effect of DTX3 overexpression on tumor growth in vivo, mice were subcutaneously inoculated with 5 × 10^5 ES-2 cells stably expressing plent-vector or plent-DTX3. Tumor growth was monitored every other day with electronic digital calipers in two dimensions. Tumor volume was calculated according to the formula: volume = length × width^2 × 0.5. Mice were sacrificed by euthanasia and tumors were then harvested, weighed, and subjected to RT-qPCR analysis. The animal protocols were in compliance with ethical regulations and approved by the Animal Welfare Committee of Shanghai Medical College at Fudan University.

Database of cancer patients

The mRNA expression correlations between DTX3 and mtp53 target genes were evaluated by the online tool GEPIA (http://gepia.cancer-pku.cn) which includes data from TCGA and GTEx database using Pearson correlation coefficient. The Oncomine database (https://www.oncomine.org) was used to analyze the DTX3 gene copy number and mRNA level in cancerous versus normal tissues. Cancer patient survival was analyzed by the Kaplan–Meier method using the KM plotter database (kmplot.com/analysis/).

Statistics

All in vitro experiments were performed in biological triplicate. The Student’s t-test or one way analysis of variance (ANOVA) was performed to evaluate the differences between two groups or more than two groups. The Cox univariate proportional hazards regression models was used to determine the independent clinical factors based on the investigated variables. Pearson’s correlation was performed to analyze the correlation of the gene expression profiling. Asterisks represent statistical significance in the following way: *, P < 0.05; ***, P < 0.01; ****, P < 0.001. All the data are presented as mean ± SD.
Results

Identification of DTX3 as a mutant p53-interacting protein

To dissect the mechanism of mtp53 regulation, we conducted a proteomic approach to screen mtp53-binding proteins in ovarian cancer tissues, resulting in the identification of the E3 ubiquitin ligase DTX3 as a new binding partner of mtp53. To validate this result, we performed a set of co-IP-IB assays to determine if DTX3 binds to mtp53 in cancer cells. As shown in Figure 1A–D, the exogenous mtp53 proteins, such as mtp53-R175H, S241F, R248W, and R273H, were co-immunoprecipitated with Flag-tagged DTX3 by the anti-Flag antibody. The results were then confirmed by the reciprocal co-IP analysis, as Flag-DTX3 could be co-immunoprecipitated with diverse p53 mutants, including mtp53-R175H, S241F, R248W, and R273H, using the anti-p53 antibody (Fig. 1E–H). Moreover, we verified the endogenous interaction of DTX3 and mtp53, as endogenous DTX3 could be co-immunoprecipitated with mtp53-R248W and R273H in ES-2 and OVCA420 cells, respectively (Fig. 1I, J). An additional ovarian cancer cell line SKOV3 stably expressing mtp53-R273H was also employed to confirm the DTX3-mtp53 interaction (Fig. 1K).

DTX3 stabilizes mutant p53 by overcoming MDM2 inhibition

Although the DTX family proteins possess E3 ubiquitin ligase activity via a conserved RING finger domain, little is known about the substrates of DTX3. Thus, we tested if DTX3 mediates mtp53 ubiquitination by in vivo ubiquitination assay. As illustrated in Figure 2A, the ubiquitination of mtp53-R273H was indeed enhanced by ectopic expression of DTX3. The effect was specific to DTX3 overexpression and not due to artifact, because the IB for inputs indicated appropriate loading of each sample (Fig. 2A). Additionally, we sought to determine which lysine(s) of ubiquitin might be required for DTX3-mediated mtp53 ubiquitination. To this end, we performed a set of in vivo ubiquitination assays using plasmids encoding wild-type or lysine-mutant ubiquitins, and found that all the lysines except for the lysine K6 are responsible for mtp53 ubiquitination (Fig. 2B, C). Thus, our results suggested that mtp53 may be modified with multiple chain types at the same time, or with a mixed ubiquitin chain, which would be tempting to investigate in the future. Interestingly, stable overexpression of DTX3 in ES-2 cells dramatically increased the level of mtp53-S241F (Fig. 2D), while knockdown of DTX3 by two independent siRNAs reduced mtp53-S241F expression (Fig. 2E). Importantly, the reduction of mtp53 level upon DTX3 siRNAs could be markedly restored when cancer cells were treated with the proteasome inhibitor MG132 (Fig. 2F), suggesting that DTX3 may stabilize mtp53 protein by blocking its proteasomal degradation. Finally, we sought
to explore the molecular basis of DTX3-induced mtp53 stabilization. Since poly-ubiquitination has been found to play a critical role in modulating protein–protein interactions, we tested if DTX3 perturbs the interaction between mtp53 and MDM2, a master E3 ubiquitin ligase that promotes proteasomal degradation of mtp53. MDM2 could be co-immunoprecipitated with mtp53-S241F by an anti-p53 antibody in ES-2 cells, while their interaction was impaired when DTX3 was stably overexpressed in these cells (Fig. 2G). Therefore, these results demonstrate that DTX3 induces mtp53 stabilization by preventing MDM2 binding to mtp53.

DTX3 activates mutant p53 target gene expression

Although p53 mutants are despoiled of their ability to associate directly with DNA elements, they can still activate gene transcription by interacting with and potentiating other transcription factors or co-factors. Thus, we determined if ectopic DTX3 induces mtp53 target gene expression through stabilization of mtp53. The lentivirus or plasmid encoding DTX3 was introduced into ES-2, OVCA420, and SKOV3-R273H cells followed by RT-qPCR analysis. As a consequence, overexpression of DTX3 significantly elevated the expression of mtp53 target genes (Fig. 3A–C). Conversely, ablation of DTX3 dramatically repressed mtp53 target gene expression (Fig. 3D). These target genes are associated with a wide range of cellular processes. For instance, IGFBP3, MAP2K3, MYC, NFkB2, CXCL1, and BCL2L1 are required for cell survival and proliferation. BUB1, CCNB1, CCNA2, NCAF1, and CENPA are critical for cell cycle progression. PXN, ITGA6, and MMP13 are diver genes of EMT and metastasis. RANGAP1 and ARHGDIA are responsible for energetic metabolism. We further validated that the effect of DTX3 is due to regulation of mtp53, because depleting mtp53 by siRNA completely restored the gene expression levels induced by DTX3 (Fig. 3E).

Next, we explored if DTX3-induced activation of mtp53 could be reflected in ovarian carcinomas. In agreement with the cell-base experiments, we revealed a positive correlation between the expression of DTX3 and some of the mtp53 target genes by mining the TCGA database (Fig. 3F–J). These correlations also suggest that DTX3 might promote ovarian cancer cell cycle progression, proliferation, survival, migration, and lipid metabolism. Collectively, these results demonstrate that DTX3 upregulates gene expression by activating mtp53, which might lead to the tumorigenic outcome.

DTX3 promotes ovarian cancer cell proliferation and invasion dependent on mutant p53

Since DTX3 modulates the expression of a broad spectrum of mtp53 target genes, we determined if this could lead to its biological function in ovarian cancer development. A set of CCK-8 cell viability assays was performed using mtp53-
containing ES-2 and OVCA420 cells. Ectopic DTX3 significantly accelerated the proliferation of ES-2 and OVCA420 cells (Fig. 4A, B), while ablation of DTX3 by two independent siRNAs retarded cell proliferation (Fig. 4C). Also, the flow cytometry analysis showed that ectopic DTX3 significantly suppresses apoptosis of ES-2 cells (Fig. 4D). These observations were in concordance with the former results showing that DTX3 activates a number of proliferation-associated genes (Fig. 3). In addition, the transwell cell invasion assay was conducted to test if DTX3 regulates cancer cell metastasis, as it also promoted the expression of metastasis-driving genes (Fig. 3). As shown in Figure 4E, ectopic DTX3 drastically boosted the invasive potential of OVCA420 cells. Conversely, knockdown of DTX3 markedly inhibited ES-2 cell invasion (Fig. 4F). Therefore, these results demonstrate that DTX3 acts as an oncogenic protein in the development of ovarian cancer.

Next, we wondered if mtp53 is required for DTX3-stimulated cancer cell proliferation and invasion. Ectopic DTX3 significantly motivated OVCA420 cell proliferation, while depletion of mtp53 impaired the effect of DTX3 on cell growth (Fig. 5A). This observation was also validated using two isogenic cell lines, SKOV3 and SKOV3-R273H. Ectopic DTX3 promoted SKOV3-R273H cell proliferation, but had a trivial effect on proliferation of p53-null SKOV3 cells (Fig. 5B). Consistently, overexpression of DTX3 triggered invasion of ES-2 and OVCA420 cells, but the effect was abolished by depletion of mtp53 in these cells (Fig. 5C, D). Altogether, these findings demonstrate that DTX3 motivates ovarian cancer growth and metastasis through activation of mtp53.

**DTX3 drives ovarian tumor growth in vivo and is associated with unfavorable prognosis**

To determine the biological function of DTX3 during ovarian carcinogenesis, we established the ovarian tumor xenograft model by subcutaneously inoculating ES-2 cells stably expressing DTX3 or the empty vector into nude mice. In agreement with the cell-based results, overexpression of DTX3 dramatically accelerated ovarian tumor growth in vivo compared with the control group as determined by the tumor volumes (Fig. 6A). Accordingly, the tumor weight and mass markedly increased because of overexpression of DTX3 (Fig. 6B, C). Next, we inquired if the increased growth of ovarian tumors is associated with activation of the mtp53 signaling pathway. Thus, the dissected tumors were further
analyzed for the expression of mtp53 target genes by RT-qPCR. In line with the former results (Fig. 3A–C), a multitude of mtp53 target genes were significantly upregulated in DTX3-overexpressing tumors (Fig. 6D). To translate our findings to clinical significance, we examined the expression of DTX3 in normal and cancerous ovarian tissues through the Oncomine database (http://www.oncomine.org/). DTX3 was found to be amplified and overexpressed in ovarian carcinomas compared with normal tissues (Fig. 6E, F). The Kaplan–Meier survival analysis (kmplot.com) further unveiled that the higher level of DTX3 is associated with worse prognosis of ovarian cancer (Fig. 6G). Taken together, these findings demonstrate that high level of DTX3 is significantly associated with the progression of ovarian cancer in xenograft-bearing mice and human patients.

**Discussion**

Ovarian cancer sustains the highest frequency of TP53 gene mutation across all human cancers. mtp53 has been shown to play an essential role in predisposition, progression, and therapeutic resistance of ovarian carcinomas. Thoroughly elucidating the regulation of mtp53 activity is of critical importance for better understanding of the mechanism and treatment of this cancer. In this study, we uncovered that the E3 ubiquitin ligase DTX3 interacts with and induces ubiquitination of mtp53. Interestingly, high level of DTX3 enhanced stabilization of mtp53 by preventing MDM2’s association and inhibition of the latter, consequently leading to mtp53-dependent activation of proliferation- and metastasis-associated gene expression (Fig. 7). Hence, our study as presented above has demonstrated an oncogenic DTX3-mtp53 axis in ovarian cancer.

The DTX family of E3 ligases contains a highly conserved C-terminal RING finger domain and has been found to mediate ubiquitination and degradation of various substrates.26 DTX1, DTX2, and DTX4 are able to modulate the NOTCH signaling by physically interacting with the intracellular domain of NOTCH via the N-terminal basic domains.26,27 Interestingly, DTX1 was identified as a target gene that is transcriptionally regulated by NOTCH1, as thus forming a feedback regulatory circuit.40 Additionally, DTX1 was found to be involved in lymphocyte development by negatively regulating NOTCH1 and, for example, MEKK1.30,41 However, DTX3 is an underappreciated E3 ubiquitin ligase whose substrates and biological function remain incompletely understood. Previous studies indicated that DTX3 may be incapable of interacting with NOTCH, as it lacks the critical motif responsible for the binding. Interestingly, it was recently reported that DTX3 can bind to and prompt degradation of NOTCH2 in esophageal carcinoma cells, resulting in the inhibition of cancer cell growth and proliferation.42 This might be a cancer context-specific interaction between DTX3 and NOTCH, which advanced our knowledge of DTX3’s function in esophageal cancer. Our findings, by contrast, revealed that DTX3 acts as a tumor promoter by interacting with and bolstering mtp53 activity in ovarian cancer. Ectopic DTX3 boosted proliferation and suppressed apoptosis of ovarian cancer cells (Fig. 4A, B, D), while knockdown of DTX3 retarded ovarian cancer cell growth (Fig. 4C). Also, overexpression of DTX3 promoted, whereas ablation of DTX3 inhibited, ovarian cancer cell invasion (Fig. 4E, F). Consistently, the tumor xenograft mouse model also showed that overexpression of DTX3 prompts ovarian tumor growth in vivo (Fig. 6A–C). Further supporting this notion was that DTX3 is amplified and overexpressed in ovarian carcinomas.
Therefore, these findings convincingly demonstrate that DTX3 promotes ovarian carcinoma cell growth and propagation as an oncogenic protein, and as thus is significantly associated with clinical outcomes of ovarian cancer.

Our study further elaborated that DTX3 exerts the pro-tumorigenic effect by enhancing mtp53 activity in ovarian carcinoma. First, we showed that ectopic DTX3 increases mtp53 level, while ablation of DTX3 reduces mtp53 expression (Fig. 2D, E). Also, overexpression of DTX3 significantly induced the expression of a broad range of mtp53 target genes that are responsible for diverse biological consequences, including cell cycle progression, apoptosis resistance, EMT and metastasis, and GTP metabolism (Fig. 3A–C). Remarkably, knockdown of mtp53 completely abated the induction of these target genes (Fig. 3E), indicating that DTX3 upregulates gene expression through mtp53. In addition, we ascertained that mtp53 activity is required for the oncogenic potential of DTX3, because depletion of mtp53 significantly impairs DTX3-induced ovarian cancer cell proliferation and motility (Fig. 5). Furthermore, the DTX3-overexpressing xenograft tumors exhibited higher levels of mtp53 target genes and accelerated growth (Fig. 6A–D). Together, these results explicitly decipher the role of the DTX3-mtp53 cascade in supporting ovarian cancer development.

In our attempt to elucidate the molecular basis of DTX3 regulation of mtp53, we found that DTX3 induces mtp53 poly-ubiquitination (Fig. 2A), but, surprisingly, ubiquitination of mtp53 led to stabilization of this protein (Fig. 2D–F). The ubiquitin molecule harbors seven lysines including K6, K11, K27, K29, K33, K48, and K63. Our results showed that six of these lysines, K11, K27, K29, K33, K48, and K63, are required for DTX3-induced mtp53 ubiquitination (Fig. 2B, C). It is known that ubiquitin chains linked by different lysines can mediate diverse cellular functions or consequences of the substrates. K11- and K48-linked ubiquitin chains often trigger proteolytic degradation of the substrates, while K29- and K63-linked chains mediate protein degradation less frequently. Actually, except for the K11- and K48-linked chains, all the other chain types were reported to be associated with the regulation of protein interactions, activity, or cellular localization. We therefore speculated that DTX3-induced ubiquitination of mtp53 may alter the protein-binding capacity of the latter. Indeed, we attested that the interaction between MDM2 and mtp53 is impaired upon DTX3 induction (Fig. 6E, F), which predicts poor prognosis (Fig. 6G).
and mtp53 is impaired in the presence of DTX3 (Fig. 2G), which could be one of the reasons for DTX3-mediated mtp53 stabilization. Since mtp53 has been found to be degraded by multiple E3 ubiquitin ligases, such as PIRH2, COP1, CHIP, and TRIM71, perturbation of the interactions between these E3 ligases and mtp53 by DTX3 might be additional potential mechanisms for mtp53 stabilization. Another interesting question raised by this study is whether

Figure 6  DTX3 fosters ovarian tumor growth in vivo and is negatively associated with prognosis. (A) Stable overexpression of DTX3 in ES-2 cells enlarges the xenograft tumor volume in average. (B, C) The dissected tumors show that stable overexpression of DTX3 increases tumor weight and mass. Data are represented as mean ± SD, n = 6. (D) DTX3 activates mtp53 target gene expression in vivo. The mRNA levels of mtp53 target genes in the dissected tumors were detected by RT-qPCR analysis. (E) The DTX3 gene is amplified in ovarian cancer samples compared with blood and normal ovaries. (F) DTX3 mRNA is upregulated in cancerous versus normal ovarian tissues in the Bonome dataset. (G) High level of DTX3 is associated with poor prognosis by the Kaplan–Meier survival analysis.

Figure 7  A schematic for the regulation of mutant p53 activity by DTX3 in ovarian cancer. In ovarian cancer cells with low levels of DTX3, MDM2, binds to and promotes proteasomal degradation of mtp53 (left panel). In ovarian cancer cells that sustain high levels of DTX3, DTX3 interacts with and mediates ubiquitination of mtp53, but instead of degrading p53, this action leads to inhibition of the MDM2-mtp53 interaction, consequently stabilizing mtp53 and inducing the expression of its target genes (right panel).
Activation of mutant p53 by DTX3

DTX3-induced mtp53 ubiquitination plays a role in mtp53 interactions with other transcription factors or co-factors. Additionally, it remains unclear if DTX3 regulates wtp53 protein stability in other types of cancer whose TP53 gene is less frequently mutated, because both wtp53 and mtp53 are often regulated by the same subset of E3 ubiquitin ligases in the context of different cancers.36

Conclusion

DTX3 is an understudied E3 ubiquitin ligase and its role in human cancers remains worthwhile investigating. Our study identified DTX3 as a novel binding protein of mtp53 in ovarian carcinoma. DTX3 mediated ubiquitination and stabilization of mtp53, probably via disruption of the MDM2-mtp53 interaction, leading to upregulation of a wide range of mtp53 target genes. Therefore, our findings demonstrate for the first time that DTX3 promotes ovarian cancer cell growth and propagation in vitro and in vivo by enhancing mtp53 activity.

Ethics approval and consent to participate

The animal protocols were in compliance with ethical regulations and approved by the Animal Welfare Committee of Shanghai Medical College at Fudan University.

Author contributions

S. W., Q. H. and J. L. conducted the experiments and analyzed the data; Q. H. designed part of the studies and instructed S. W. in several experiments. Y. C. provided part of critical experimental materials; X. W. and X. Z. designed the studies and analyzed the data; X. Z. composed the manuscript; H. L. assisted in study design and data analysis, and edited the manuscript.

Conflict of interests

The authors declare no conflict of interest.

Acknowledgements

We thank Ping Zhang for flow cytometry analysis.

Funding

This study was supported by the National Natural Science Foundation of China (No. 81672566, 81874053, 81972431, and 81702352), and the Basic and Clinical Translational Research Funding from Fudan University Shanghai Cancer Center.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.gendis.2020.11.007.

References

1. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–1253.
2. Bowtell DD, Böhm S, Ahmed AA, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15(11):668–679.
3. Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489–494.
4. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–615.
5. Zhang Y, Cao L, Nguyen D, Lu H. TP53 mutations in epithelial ovarian cancer. Transl Cancer Res. 2016;5(6):650–663.
6. Levine AJ. The many faces of p53: something for everyone. J Mol Cell Biol. 2019;11(7):524–530.
7. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009;9(10):749–758.
8. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 2008;9(5):402–412.
9. Hafner A, Bulyk ML, Jambhekar A, Lahav G. The multiple mechanisms that regulate p53 activity and cell fate. Nat Rev Mol Cell Biol. 2019;20(4):199–210.
10. Liu Y, Tavana O, Gu W. p53 modifications: exquisite decorations of the powerful guardian. J Mol Cell Biol. 2019;11(7):564–577.
11. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26(12):1268–1286.
12. Bargonetti J, Prives C. Gain-of-function mutant p53: history and speculation. J Mol Cell Biol. 2019;11(7):605–609.
13. Leroy B, Anderson M, Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat. 2014;35(6):672–688.
14. Zhou X, Hao Q, Lu H. Mutant p53 in cancer therapy—the barrier or the path. J Mol Cell Biol. 2019;11(4):293–305.
15. Liao P, Zeng SX, Zhou X, et al. Mutant p53 gains its function via c-myc activation upon CDK4 phosphorylation at serine 249 and consequent PIN1 binding. Mol Cell. 2017;68(6):1134–1146.
16. Wang H, Liao P, Zeng SX, Lu H. It takes a team: a gain-of-function story of p53-R249S. J Mol Cell Biol. 2019;11(4):277–283.
17. Will K, Warnecke G, Wiesmüller L, Deppert W. Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing. Proc Nat Acad Sci U S A. 1998;95(23):13681–13686.
18. Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol. 2007;9(5):573–580.
19. Ren YA, Mullany LK, Liu Z, Herron AJ, Wong KK, Richards JS. Mutant p53 promotes epithelial ovarian cancer by regulating tumor differentiation, metastasis, and responsiveness to steroid hormones. Cancer Res. 2016;76(8):2206–2218.
20. Leiwen S, van Geel RM, Sonke GS, et al. Phase II study of WEE1 inhibitor AZD1775 Plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. J Clin Oncol. 2016;34(36):4354–4361.
21. Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002;8(3):282–288.
22. Aning OA, Cheok CF. Drugging in the absence of p53. J Mol Cell Biol. 2019;11(3):255–264.
23. Chen Y, Hao Q, Wang J, et al. Ubiquitin ligase TRIM71 suppresses ovarian tumorigenesis by degrading mutant p53. Cell Death Dis. 2019;10(10):737.
24. Xu T, Artavanis-Tsakonas S. deltex, a locus interacting with the neurogenic genes, Notch, Delta and mastermind in Drosophila melanogaster. *Genetics*. 1990;126(3):665–677.

25. Gorman MJ, Girton JR. A genetic analysis of deltex and its interaction with the Notch locus in Drosophila melanogaster. *Genetics*. 1992;131(1):99–112.

26. Takeyama K, Aguiar RC, Gu L, et al. The BAL-binding protein BBAP and related Deltex family members exhibit ubiquitin-protein isopeptide ligase activity. *J Biol Chem*. 2003;278(24):21930–21937.

27. Zweifel ME, Leahy DJ, Barrick D. Structure and Notch receptor binding of the tandem WWE domain of Deltex. *Structure*. 2005;13(11):1599–1611.

28. Matsuno K, Eastman D, Mitsiades T, et al. Human deltex is a conserved regulator of Notch signalling. *Nat Genet*. 1998;19(1):74–78.

29. Yamamoto N, Yamamoto S, Inagaki F, et al. Role of Deltex-1 as a transcriptional regulator downstream of the Notch receptor. *J Biol Chem*. 2001;276(48):45031–45040.

30. Izon DJ, Aster JC, He Y, et al. Deltex1 redirects lymphoid progenitors to the B cell lineage by antagonizing Notch1. *Immunity*. 2002;16(2):231–243.

31. Zhang P, Yang Y, Holo R, Zweidler-Mckay PA, Hughes DP. Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness. *Oncogene*. 2010;29(20):2916–2926.

32. Chastagner P, Rubinstein E, Brou C. Ligand-activated Notch undergoes DTX4-mediated ubiquitylation and bilateral endocytosis before ADAM10 processing. *Sci Signal*. 2017;10(483):eaag2989.

33. Gatza ML, Silva GO, Parker JS, Fan C, Perou CM. An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. *Nat Genet*. 2014;46(10):1051–1059.

34. Hao Q, Wang J, Chen Y, et al. Dual regulation of p53 by the ribosome maturation factor SBDS. *Cell Death Dis*. 2020;11(3):197–15.

35. Zhou X, Hao Q, Liao P, et al. Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator. *Elife*. 2016;5:e15099.

36. Hao Q, Chen Y, Zhou X. The janus face of p53-targeting ubiquitin ligases. *Cells*. 2020;9(7):1656.

37. Komander D, Rape M. The ubiquitin code. *Annu Rev Biochem*. 2012;81:203–229.

38. Terzian T, Suh YA, Iwakuma T, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. *Genes Dev*. 2008;22(10):1337–1344.

39. Peng Y, Chen L, Li C, Lu W, Chen J. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. *J Biol Chem*. 2001;276(44):40583–40590.

40. Deftos ML, Huang E, Ojala EW, Forbush KA, Bevan MJ. Notch1 signaling promotes the maturation of CD4 and CD8 SP thymocytes. *Immunity*. 2000;13(1):73–84.

41. Liu WH, Lai MZ. Deltex regulates T-cell activation by targeted degradation of active MEKK1. *Mol Cell Biol*. 2005;25(4):1367–1378.

42. Ding XY, Hu HY, Huang KN, et al. Ubiquitination of NOTCH2 by DTX3 suppresses the proliferation and migration of human esophageal carcinoma. *Cancer Sci*. 2020;111(2):489–501.

43. Bonome T, Levine DA, Shih J, et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. *Cancer Res*. 2008;68(13):5478–5486.